Due to the occurrence of tuberculosis cases in the early years of TNF blocker treatments, physicians were sensitized to this issue, which is why LTBI often became a reason for exclusion in approval studies for newer bDMARDs and tsDMARDs or LTBI was treated preventively. The gene discussed is TNF; the disease is tuberculosis.